Patient
P2B-106
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · University of Iowa (Iowa City, IA) (Dr. Okafor)
consented 2013-04-26
Adverse events
8
Serious AEs
3
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 leukopenia with onset in cycle 6 (2013-09-05); assessed as related to study drug (probable); resolved 2013-09-11.
Grade 1 cough with onset in cycle 4 (2013-07-31); assessed as not related to study drug (unlikely); resolved 2013-08-09.
Grade 1 fatigue with onset in cycle 4 (2013-07-17); assessed as not related to study drug (not related); resolved 2013-08-12.
Grade 3 pelvic neoplasm with onset in cycle 2 (2013-06-12); serious (hospitalization); assessed as not related to study drug (unlikely); resolved 2013-06-22.
Grade 3 deep vein thrombosis with onset in cycle 2 (2013-06-03); serious (hospitalization); assessed as not related to study drug (unlikely); resolved 2013-06-22; action: drug interrupted.
Grade 2 alopecia with onset in cycle 1 (2013-05-23); assessed as related to study drug (probable); not resolved at last follow-up.
Grade 3 leukopenia with onset in cycle 1 (2013-05-17); serious (hospitalization); assessed as related to study drug (probable); resolved 2013-05-24.
Grade 3 neutropenia with onset in cycle 1 (2013-05-16); assessed as related to study drug (probable); resolved 2013-05-25; action: drug interrupted.
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.